A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation

Biochemical and Biophysical Research Communications

Volumn 432, Issue 4, 2013, Pages 564-567

  Kato, Yukinari ^a,b   Natsume, Atsushi ^c   Kaneko, Mika Kato ^a,b  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

IDH1; IDH1 mutation; MAb; Monoclonal antibody; R132G

Indexed keywords

GMAB M1 MONOCLONAL ANTIBODY; HMAB M1 MONOCLONAL ANTIBODY; ISOCITRATE DEHYDROGENASE 1; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; GLIOMA CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; WESTERN BLOTTING;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, MONOCLONAL; ARGININE; CELL LINE; CRICETINAE; GLIOMA; GLYCINE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; MICE; MUTATION; RATS; STAINING AND LABELING;

MUS;

EID: 84875495646     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.02.049     Document Type: Article

References (16)

1. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., Marks K.M., Prins R.M., Ward P.S., Yen K.E., Liau L.M., Rabinowitz J.D., Cantley L.C., Thompson C.B., Vander Heiden M.G., Su S.M. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-744.
2. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K.W., Velculescu V.E., Vogelstein B., Bigner D.D. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360:765-773.
3. Pansuriya T.C., van Eijk R., d'Adamo P., van Ruler M.A., Kuijjer M.L., Oosting J., Cleton-Jansen A.M., van Oosterwijk J.G., Verbeke S.L., Meijer D., van Wezel T., Nord K.H., Sangiorgi L., Toker B., Liegl-Atzwanger B., San-Julian M., Sciot R., Limaye N., Kindblom L.G., Daugaard S., Godfraind C., Boon L.M., Vikkula M., Kurek K.C., Szuhai K., French P.J., Bovee J.V. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat. Genet. 2011, 43:1256-1261.
4. Amary M.F., Damato S., Halai D., Eskandarpour M., Berisha F., Bonar F., McCarthy S., Fantin V.R., Straley K.S., Lobo S., Aston W., Green C.L., Gale R.E., Tirabosco R., Futreal A., Campbell P., Presneau N., Flanagan A.M. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat. Genet. 2011, 43:1262-1265.
5. Ward P.S., Patel J., Wise D.R., Abdel-Wahab O., Bennett B.D., Coller H.A., Cross J.R., Fantin V.R., Hedvat C.V., Perl A.E., Rabinowitz J.D., Carroll M., Su S.M., Sharp K.A., Levine R.L., Thompson C.B. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-234.
6. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., Olivi A., McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H., Diaz L.A., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K., Shinjo S.M., Yan H., Riggins G.J., Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
7. Sonoda Y., Kumabe T., Nakamura T., Saito R., Kanamori M., Yamashita Y., Suzuki H., Tominaga T. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer sci. 2009, 100:1996-1998.
8. Balss J., Meyer J., Mueller W., Korshunov A., Hartmann C., von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008, 116:597-602.
9. Hartmann C., Meyer J., Balss J., Capper D., Mueller W., Christians A., Felsberg J., Wolter M., Mawrin C., Wick W., Weller M., Herold-Mende C., Unterberg A., Jeuken J.W., Wesseling P., Reifenberger G., von Deimling A. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol. 2009, 118:469-474.
10. von Deimling A., Korshunov A., Hartmann C. The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol. 2011, 21:74-87.
11. Capper D., Zentgraf H., Balss J., Hartmann C., von Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 2009, 118:599-601.
12. Kato Y., Jin G., Kuan C.T., McLendon R.E., Yan H., Bigner D.D. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem. Biophys. Res. Commun. 2009, 390:547-551.
13. Kaneko M.K., Tian W., Takano S., Suzuki H., Sawa Y., Hozumi Y., Goto K., Yamazaki K., Kitanaka C., Kato Y. Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. Biochem. Biophys. Res. Commun. 2011, 406:608-613.
14. Takano S., Kato Y., Yamamoto T., Kaneko M.K., Ishikawa E., Tsujimoto Y., Matsuda M., Nakai K., Yanagiya R., Morita S., Tsuboi K., Matsumura A. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. J. Neurooncol. 2012, 108:361-373.
15. Kaneko M., Morita S., Tsujimoto Y., Yanagiya R., Nasu K., Sasaki H., Hozumi Y., Goto K., Natsume A., Watanabe M., Kumabe T., Takano S., Kato Y. Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations. Biochem. Biophys. Res. Commun. 2013, 432:40-45.
16. Y. Kato, M.K. Kaneko, Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation, Biochem. Biophys. Res. Commun. (2013), in press.